Accelerated failure time survival model for prostate cancer
Keywords:Prostate cancer, Survival analysis, Accelerated failure time
Background: Prostate cancer is the second most common cancer in men globally and ranks sixth among male cancer-related deaths. This study utilized survival analysis to assess post-diagnosis outcomes, aiming to enhance prostate cancer patient longevity. Insights were gained by determining median survival times, identifying prognostic factors, and applying an AFT model to prostate cancer data.
Methods: The study collected data from 502 prostate cancer patients featured in a 1980 paper by D. P. Byar and S. B. Green, focusing on stage 3 or 4 cases. Over six years, they monitored these patients' survival under varying estrogen doses, analyzing 15 variables. Data import was done using excel, R and SPSS were used for the analysis. Utilizing the Kaplan-Meier method and AFT models, the study identified predictive factors and determined the most suitable model for prostate cancer analysis.
Results: Among the 502 patients, 70.7% died, and 29.3% were right-censored, with a median survival of 35 months. Factors enhancing survival included a 1.0 mg estrogen dose, higher body weight, and elevated serum hemoglobin levels. In contrast, age, tumor size, cardiovascular disease history, and a composite index of stage and histology grade were associated with reduced survival odds in prostate cancer patients.
Conclusions: Prostate cancer patients had a median survival of 35 months, with survival rates at 60 months (31.7%) and 75 months (23.2%). The 1.0 mg estrogen dose proved most effective among tested doses. The Weibull AFT model, with an AIC score of 3469.032, was the best-fit model.
Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M et al Global Cancer Observatory: cancer today. Lyon (France). International Agency for Research on Cancer. 2018. Available at: https://gco.iarc.fr/today/home. Accessed on 08 August, 2023.
Chidebe RCW, Orjiakor CT, Pereira I, Ipiankama SC, Lounsbury DW, Moraes FY. Navigating prostate cancer control in Nigeria. Lancet Oncol. 2019;20(11):1489-91.
Howlader AMN, Krapcho M, Neyman N, Aminou R SEER Cancer Statistics Review, 1975-2008, National Cancer Institute, Bethesda, Md, USA, 2011. Available at: http://seer.cancer.gov/csr/19752008/. Accessed on 08 August, 2023.
Shamsul A, Norzaher I, Syafiq T, Siti NM, Nazarudin S. Survival Analysis and Prognostic Factors for Prostate Cancer Patients at Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur. Sains Malaysiana. 2021;50(5):1367-79.
Singh R, Mukhopadhyay K. Survival analysis in clinical trials: Basics and must know areas. Perspectives Clin Res. 2011;2(4):145-8.
Nesbit RM. Prostatic carcinoma: A follow-up on 795 patients treated prior to the endocrine era and a comparison of survival rates between these and patients treated by endocrine therapy. Surgery. 1946;20:263-72.
Hong GE, Kong CH, Singam P, Cheok LB, Zainuddin ZM, Azrif M. Seven-year review of prostate carcinomas diagnosed by TRUS biopsy in a single Malaysian institution. Asian Pacific J Cancer Prevent. 2010;11(5):1351-3.
Phanphaisarn A, Patumanond J, Settakorn J, Chaiyawat P, Klangjorhor J. Prevalence and survival patterns of patients with bone metastasis from common cancers in Thailand. Asian Pacific J Cancer Prevent. 2016;17(9):4335-40.
Lova S, Ravi BP, Rebecca AH, John C, Samuel UT, David JV et al. Assessment and Management of Cardiovascular Risk Factors Among US Veterans with Prostate Cancer. 2021;4(2):e210070.
Zahir ST, Nazemian MR, Zand S, Zare S. Survival of patients with prostate cancer in Yazd, Iran. Asian Pacific J Cancer Prevent. 2014;15(2):883-6.
Bechis SK, Carroll PR, Cooperberg MR. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol. 2011;29(2):235-41.
Subahir MN, Shah SA, Zainuddin ZM. Risk factors for prostate cancer in Universiti Kebangsaan Malaysia Medical Centre: A case-control study. Asian Pacific J Cancer Prevent. 2009;10(6):1015-20.